medigraphic.com
ISSN 1561-3054 (Electronic)

2013, Number 1

<< Back Next >>

Rev Cubana Med Trop 2013; 65 (1)

Phenotypic characterization of enterobacteria isolated from patients with human immunodeficiency virus infection/AIDS

García CT, Salazar RD, Castillo KF, Rodríguez SW, Reyes RT

Language: Spanish
References: 25
Page: 66-77
PDF size: 255.86 Kb.


ABSTRACT

Introduction: the risk of infections caused by enterobacteria increases in HIV patients.
Objective: to phenotypically characterize the enterobacteria responsible for infections in these patients.
Methods: a prospective and descriptive study was conducted in "Pedro Kourí" Institute from March 2010 to March 2011. Samples of sputum, bronchial lavage, pharyngeal, ear and vaginal secretions, urine, stool, skin lesions, blood and catheters taken from 65 patients (ambulatory and hospital) were processed. Bacterial identification and antimicrobial susceptibility of 73 isolates were determined by automated system VITEK 2 Compact (bioMérieux, France).
Results: Escherichia coli (30), Klebsiella spp. (19), Enterobacter spp. (15), Proteus spp. (7) and Serratia spp. (2) were identified. Sepsis in hospitalized patients (87.7 %) was prevalent. Less than 50 % of Enterobacteriaceae were resistant to cephalosporins, except Klebsiella spp. and Enterobacter spp. (68.4 % and 93.3 % resistance to cefepime and cefoxitin, respectively) and over 80% were sensitive to amykacin. Resistance to piperacillin/tazobactam and ciprofloxacin was observed in 27.3 % and 15 % of cases, respectively. In the study, 34.2 % of extended-spectrum beta-lactamases- producing strains was detected.
Conclusions: Escherichia coli and Klebsiella spp. often cause infections in HIV patients. The study of antimicrobial susceptibility by using VITEK 2 Compact system, suggests that cephalosporins, aminoglycosides, quinolones and piperacillin/tazobactam, could be effective therapeutic alternatives in these cases.


REFERENCES

  1. Caiaffa WT, Graham NM, Vlahov D. Bacterial Pneumonia in adult populations with human immunodeficiency virus (HIV) infection. Am J Epidemiol. 1993;138:909-22.

  2. Morpeth SC, Thielman NM, Ramadhani HO, Hamilton JD, Ostermann J, Kisenge PR, et al. Effect of trimethoprim-sulfamethoxazole prophylaxis on antimicrobial resistance of fecal Escherichia coli in HIV-infected patients in Tanzania. J Acquir Immune Defic Syndr. 2008;47(5):585-91.

  3. Jordá L, Vila A, Lanza A, Bonvehi P, Nazar J, Mikietuk A, et al. Utilidad del sistema VITEK en la identificación bacteriana y estudios de sensibilidad antimicrobiana. Acta Bioquím Clín Latinoam. 2005;39(1):19-25.

  4. Salami AK, Olatunji PO, Oluboyo PO, Akanbi AA, Fawibe EA. Bacterial pneumonia in the AIDS patients. West Afr J Med. 2006;25(1):1-5.

  5. Petrosillo N, Nicastri E, Viale P. Nosocomial pulmonary infections in HIV-positive patients. J Clin Microbiol. 2005;11(3):231-5.

  6. Feikin DR, Feldman C, Schuchat A, Janoff EN. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis. 2004;4:445-55.

  7. Omoregie R, Eghafona NO. Urinary tract infection among asymptomatic HIV patients in Benin City, Nigeria. Br J Biomed Sci. 2009;66(4):190-3.

  8. Navarro F, Miró E, Mirelis B. Lectura interpretación del antibiograma de enterobacterias. Enf Infecc Microbial Clin. 2010;28(9):638-45.

  9. Morejón M. Inhibidores de betalactamasas asociados con penicilinas. En: Morejón M, Salup Díaz, Cue Brugueras, editors. Actualización en antimicrobianos sistémicos. La Habana: Editorial Ciencias Médicas; 2005. p. 61-6.

  10. De la Parte-Pérez MA, Brito A, Guzmán M, Carmona O. Resistencia de Klebsiella pneumoniae a los antimicrobianos en Venezuela. Análisis de una década. Rev Soc Ven Microbiol. 2001Jul;21(2):14-22.

  11. Lee K, Lim CH, Cho JH, Lee WG, Uh Y, Kim HJ. High prevalence of ceftazidime-resistant Klebsiella pneumoniae and increase of imipenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. in Korea: a KONSAR program in 2004. Yonsei Med J. 2006;47(5):634-45.

  12. Rodríguez C, Martínez J. Vigilancia microbiológica en infecciones respiratorias bajas. Rev Cubana Hig Epidemiol. 2002Sep-Dic;40(3):189-202. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-30032002000300004&lng=es&nrm=iso&tlng=es

  13. Jacoby GA, Muñoz-Price LS. The new ß-lactamases. N Engl J Med. 2005;352:380-91.

  14. Regueiro B, García-Riestra C, Varón C, Martínez-Lamas L, Moldes L, Treviño M, et al. Comparación entre las pruebas para la detección de betalactamasas de espectro extendido de los sistemas Vitek 2 y Phoenix. Enf Inf Microbiol Clín. 2009;27(10):566-70.

  15. Rupp ME, PD Fey. Enterobacterias Productoras de ß-lactamasas de espectro extendido (BLEE). Diagnóstico, prevención y tratamiento farmacológico. Drugs. 2003;63(4):353-65.

  16. Cotton M, Wasserman E, Smit J, Whitelaw A, Zar HJ. High incidence of antimicrobial resistant organisms including extended spectrum beta-lactamase producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus in nasopharyngeal and blood isolates of HIV-infected children from Cape Town, South Africa. BMC Infectious Diseases. 2008[citado 2 abril 2010];8:40[about 2 p]. Disponible en: http://www.biomedcentral.com/1471-2334/8/40

  17. Díaz P, Bello H, Domínguez M, Trabal N, Mella S, Zemelman R, et al. Resistencia a gentamicina, amikacina y ciprofloxacina en cepas hospitalarias de Klebsiella pneumoniae subespecie pneumoniae productoras de beta-lactamasas de espectro extendido. Rev Med Chil. 2004;(10):1173-8.

  18. Shanthi M, Sekar U. Extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact. of resistance on outcomes. J Assoc Physicians. 2010;58:Suppl 41-4. Disponible en: http://www.japi.org/antibiotic_special_dec_issue_2010/article_10.html

  19. Abhilash KP, Veeraraghavan B, Abraham OC. Epidemiology and outcome of bacteremia caused by extended spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp. in a tertiary care teaching hospital in south India. J Assoc Physicians India. 2010;58:7-13.

  20. Deshpande P, Rodriguez C, Shetty A , Kapadia F, Hedge A, Soman R. New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae: treatment options with carbapenems compromised. J Assoc Physicians India. 2010;58:147-9.

  21. Htoutou M, Hanulík V, Chromák M, Hricovák K, Senkýøová M, Koláø M. Resistance of Enterobacteriaceae to carbapenems. Klin Mikrobiol Infekc Lek. 2011 Feb;17(1):12-8.

  22. Irfan S, Idrees F, Mehraj V, Habib F, Adil S, Hasan R. Emergence of Carbapenem resistant Gram negative and vancomycin resistant Gram positive organisms in bacteremic. BMC Infectious Diseases. 2008[citado 6 may 2010];8:80[about 2 p]. Disponible en: http://www.biomedcentral.com/1471-2334/8/80

  23. Vakulenko S, Mobashery S. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev. 2003;16:430-50.

  24. Calvo J, Cantón R, Fernández F, Mirelis B, Navarro F. Detección fenotípica de mecanismos de resistencia en gramnegativos. En: Cercenado E, Cantón R, editores. Procedimientos en Microbiología Clínica. 2ª ed. Madrid: Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica; 2011. 2003 [citado 7 marzo 2010]. Disponible en: http://www.seimc.org/documentos/protocolos/microbiologia/cap39indice.htm

  25. Oliver A, Cantón R. Enterobacterias productoras de ß-lactamasas plasmídicas de espectro extendido [Internet]. Madrid: Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica; 2003 [citado 7 marzo 2010]. Disponible en: http://www.seimc.org/control/revisiones/bacteriologia/Blees.pdf




2020     |     www.medigraphic.com